-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
4E2RCat
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/432499-63-3.gif)
| Category | Virus Protease |
| CAS | 432499-63-3 |
| Description | 4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM. |
Product Information
| Synonyms | 4E2RCat|432499-63-3|5-(5-((3-Benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)-2-chlorobenzoic acid|MFCD03706106|NB-217|ZINC33313682|AT14170|CS-6204|NCGC00686697-01|BS-51906|HY-100733|5-[5-[(Z)-(3-benzyl-4-oxo-2-thioxo-thiazolidin-5-ylidene)methyl]-2-furyl]-2-chloro-benzoic acid|Benzoic acid, 2-chloro-5-[5-[(Z)-[3-phenylmethyl-4-oxo-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]- |
| Molecular Weight | 455.93 |
| Molecular Formula | C22H14ClNO4S2 |
| Canonical SMILES | C1=CC=C(C=C1)CN2C(=O)C(=CC3=CC=C(O3)C4=CC(=C(C=C4)Cl)C(=O)O)SC2=S |
| Boiling Point | 659.0±65.0 °C at 760 mmHg |
| Flash Point | 352.3±34.3 °C |
| Purity | >98% |
| Density | 1.6±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 23.33 mg/mL(51.17 mM;Need ultrasonic) In Vivo: 1. Add each solvent one by one:10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.33 mg/mL (5.11mM); Clear solution |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 724 |
| Exact Mass | 455.005280 |
| Index Of Refraction | 1.760 |
| In Vitro | 4E2RCat prevents the interaction between eIF4E and eIF4G, inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. In addition, it inhibits coronavirus replication in a dose- and time-dependent manner. |
| In Vivo | 4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death. |
| Target | Eukaryotic Initiation Factor (eIF); Autophagy; Virus Protease |
| Vapor Pressure | 0.0±2.1 mmHg at 25°C |
| XLogP3-AA | 5.4 |
